Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene Results From a 3- Year Randomized Clinical Trial
نویسندگان
چکیده
phene that binds ta estrogen receptars and inhibits bone resorption without stimulating the uterine endametrium in pastmenapausal women.1 However, the effect of raloxifene on the risk of fracture is not knawn. Observational studies in postmenapausaI women have suggested that langterm estragen therapy reduces the inciContext Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.
منابع مشابه
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
BACKGROUND Vertebral fractures increase the risk of new vertebral fractures; however, we are not aware of any study addressing the risk of new vertebral fractures adjacent to existing vertebral fractures. Therefore, we sought to determine the influence of the number and severity of prevalent (preexisting) vertebral fractures on the risk of new adjacent vertebral fractures and to determine wheth...
متن کاملEarly effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
BACKGROUND Raloxifene hydrochloride therapy reduces the risk for vertebral fractures at 3 years, but the effects on clinical vertebral fractures in the first year are not known. METHODS The Multiple Outcomes of Raloxifene Evaluation (MORE) Trial enrolled 7705 women with osteoporosis, defined by prevalent vertebral fractures and/or a bone mineral density (BMD) T score at or below -2.5, who wer...
متن کاملCost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
BACKGROUND The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis. OBJECTIVE Based on the MORE study the aim of the present study was to assess the cost effectiveness of raloxifene (compared with no treatment) for the treatment of osteoporosis in postme...
متن کاملRisedronate treatment and extended fracture protection in postmenopausal women.
Sir, I would like to provide some perspective with regard to a published comment (1) on our study of risedronate treatment in postmenopausal women with vertebral fracture (2). The author suggests that risedronate is not effective in reducing vertebral fracture risk after the first year, and that the effects of risedronate "do not compare favorably" with those of alendronate and raloxifene. This...
متن کاملTreating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, strontium, parathyroid hormone, and selective estrogen receptor modulators (SERM). Advantages and disadvantages exist for each category as some patients may, for example, not tolerate bisphosphonates for gastrointestinal side effects, and especially in women in whom osteoporosis is frequent, several options ...
متن کامل